Previous 10 | Next 10 |
Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations - Company Reports Third Quarter Revenues of $265.0 Million, GAAP Net Loss per Share of $0.00 and Basic and Diluted Non-GAAP Earnings per Share of $0.26 - - ARISTADA® Net Sal...
Alkermes (NASDAQ:ALKS) is scheduled to announce Q3 earnings results on Thursday, October 29th, before market open.The consensus EPS Estimate is $0.00 (+100.0% Y/Y) and the consensus Revenue Estimate is $238.39M (-6.6% Y/Y).Over the last 2 years, ALKS has beaten EPS estimates 88% of the time a...
Alkermes (ALKS) has been moving in a sideways trading range and formed a rectangle pattern. The stock appears to be heading towards its support line. Learn when to enter a trade to profit from this move. Over the past three months, Alkermes ( ALKS ) has been in a sideways trading range an...
Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results PR Newswire DUBLIN, Oct. 22, 2020 DUBLIN , Oct. 22, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ...
Alkermes (ALKS) announced overwhelming and surprising positive votes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, notes John McCamant, editor of The Medical Technology Stock Letter. For further details...
Bristol-Myers Squibb reports positive data for Zeposia. Alkermes receives favorable FDA advisory board response for ALKS 3831. Seagen reports positive data from Phase 2 PADCEV study. For further details see: Bristol-Myers Squibb Reports Positive Data, And Other News: The...
Alkermes (ALKS) +15.3% after-hours, following news that U.S. Food and Drug Administration advisory committees examining its ALKS 3831 (olanzapine/ samidorphan) determined that samidorphan meaningfully mitigates olanzapine-associated weight gain and that the safety profile of ALKS 3831 is...
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder PR Newswire DUBLIN, Oct. 9, 2020 DUBLIN , Oct. 9, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive voting outco...
Trading in Alkermes Ordinary Shares Halted Today -- FDA Advisory Committee to Review New Drug Application for ALKS 3831 for the Treatment of Adults with Schizophrenia or Bipolar I Disorder -- PR Newswire DUBLIN, Oct. 9, 2020 DUBLIN , Oct. 9, 2020 /PRNewsw...
Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831 PR Newswire DUBLIN, Oct. 7, 2020 DUBLIN , Oct. 7, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administrat...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 10:45:03 ET Enbridge Inc (ENB) ENB is trading UP for the last 5 days, and it at trading at $36.59 with volume of 731,965 and a one day change of $0.05 (0.14%). Enbridge Inc has a 52-week low of 31.03 and a 52-week high of $38.36. The business's 50-day moving average price...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...